Nurix Therapeutics, Inc. NRIX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s cash & equivalents?
- Nurix Therapeutics, Inc. (NRIX) reported cash & equivalents of $72.16M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Nurix Therapeutics, Inc.'s cash & equivalents decreased by 6.1% year-over-year, from $76.82M to $72.16M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s cash & equivalents has grown at a 15.7% compound annual growth rate (CAGR), from $119.36M to $247.93M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.